Cargando…

The @RISK Study: Risk communication for patients with type 2 diabetes: design of a randomised controlled trial

BACKGROUND: Patients with type 2 diabetes mellitus (T2DM) have an increased risk to develop severe diabetes related complications, especially cardiovascular disease (CVD). The risk to develop CVD can be estimated by means of risk formulas. However, patients have difficulties to understand the outcom...

Descripción completa

Detalles Bibliográficos
Autores principales: Welschen, Laura MC, Bot, Sandra DM, Dekker, Jacqueline M, Timmermans, Daniëlle RM, van der Weijden, Trudy, Nijpels, Giel
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2922111/
https://www.ncbi.nlm.nih.gov/pubmed/20687924
http://dx.doi.org/10.1186/1471-2458-10-457
_version_ 1782185418518691840
author Welschen, Laura MC
Bot, Sandra DM
Dekker, Jacqueline M
Timmermans, Daniëlle RM
van der Weijden, Trudy
Nijpels, Giel
author_facet Welschen, Laura MC
Bot, Sandra DM
Dekker, Jacqueline M
Timmermans, Daniëlle RM
van der Weijden, Trudy
Nijpels, Giel
author_sort Welschen, Laura MC
collection PubMed
description BACKGROUND: Patients with type 2 diabetes mellitus (T2DM) have an increased risk to develop severe diabetes related complications, especially cardiovascular disease (CVD). The risk to develop CVD can be estimated by means of risk formulas. However, patients have difficulties to understand the outcomes of these formulas. As a result, they may not recognize the importance of changing lifestyle and taking medication in time. Therefore, it is important to develop risk communication methods, that will improve the patients' understanding of risks associated with having diabetes, which enables them to make informed choices about their diabetes care. The aim of this study is to investigate the effects of an intervention focussed on the communication of the absolute 10-year risk to develop CVD on risk perception, attitude and intention to change lifestyle behaviour in patients with T2DM. The conceptual framework of the intervention is based on the Theory of Planned Behaviour and the Self-regulation Theory. METHODS: A randomised controlled trial will be performed in the Diabetes Care System West-Friesland (DCS), a managed care system. Newly referred T2DM patients of the DCS, younger than 75 years will be eligible for the study. The intervention group will be exposed to risk communication on CVD, on top of standard managed care of the DCS. This intervention consists of a simple explanation on the causes and consequences of CVD, and possibilities for prevention. The probabilities of CVD in 10 year will be explained in natural frequencies and visualised by a population diagram. The control group will receive standard managed care. The primary outcome is appropriateness of risk perception. Secondary outcomes are attitude and intention to change lifestyle behaviour and illness perception. Differences between baseline and follow-up (2 and 12 weeks) between groups will be analysed according to the intention-to-treat principle. The study was powered on 120 patients in each group. DISCUSSION: This innovative risk communication method based on two behavioural theories might improve patient's appropriateness of risk perception and attitude concerning lifestyle change. With a better understanding of their CVD risk, patients will be able to make informed choices concerning diabetes care. TRAIL REGISTRATION: The trial is registered as NTR1556 in the Dutch Trial Register.
format Text
id pubmed-2922111
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-29221112010-08-17 The @RISK Study: Risk communication for patients with type 2 diabetes: design of a randomised controlled trial Welschen, Laura MC Bot, Sandra DM Dekker, Jacqueline M Timmermans, Daniëlle RM van der Weijden, Trudy Nijpels, Giel BMC Public Health Study Protocol BACKGROUND: Patients with type 2 diabetes mellitus (T2DM) have an increased risk to develop severe diabetes related complications, especially cardiovascular disease (CVD). The risk to develop CVD can be estimated by means of risk formulas. However, patients have difficulties to understand the outcomes of these formulas. As a result, they may not recognize the importance of changing lifestyle and taking medication in time. Therefore, it is important to develop risk communication methods, that will improve the patients' understanding of risks associated with having diabetes, which enables them to make informed choices about their diabetes care. The aim of this study is to investigate the effects of an intervention focussed on the communication of the absolute 10-year risk to develop CVD on risk perception, attitude and intention to change lifestyle behaviour in patients with T2DM. The conceptual framework of the intervention is based on the Theory of Planned Behaviour and the Self-regulation Theory. METHODS: A randomised controlled trial will be performed in the Diabetes Care System West-Friesland (DCS), a managed care system. Newly referred T2DM patients of the DCS, younger than 75 years will be eligible for the study. The intervention group will be exposed to risk communication on CVD, on top of standard managed care of the DCS. This intervention consists of a simple explanation on the causes and consequences of CVD, and possibilities for prevention. The probabilities of CVD in 10 year will be explained in natural frequencies and visualised by a population diagram. The control group will receive standard managed care. The primary outcome is appropriateness of risk perception. Secondary outcomes are attitude and intention to change lifestyle behaviour and illness perception. Differences between baseline and follow-up (2 and 12 weeks) between groups will be analysed according to the intention-to-treat principle. The study was powered on 120 patients in each group. DISCUSSION: This innovative risk communication method based on two behavioural theories might improve patient's appropriateness of risk perception and attitude concerning lifestyle change. With a better understanding of their CVD risk, patients will be able to make informed choices concerning diabetes care. TRAIL REGISTRATION: The trial is registered as NTR1556 in the Dutch Trial Register. BioMed Central 2010-08-05 /pmc/articles/PMC2922111/ /pubmed/20687924 http://dx.doi.org/10.1186/1471-2458-10-457 Text en Copyright ©2010 Welschen et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Study Protocol
Welschen, Laura MC
Bot, Sandra DM
Dekker, Jacqueline M
Timmermans, Daniëlle RM
van der Weijden, Trudy
Nijpels, Giel
The @RISK Study: Risk communication for patients with type 2 diabetes: design of a randomised controlled trial
title The @RISK Study: Risk communication for patients with type 2 diabetes: design of a randomised controlled trial
title_full The @RISK Study: Risk communication for patients with type 2 diabetes: design of a randomised controlled trial
title_fullStr The @RISK Study: Risk communication for patients with type 2 diabetes: design of a randomised controlled trial
title_full_unstemmed The @RISK Study: Risk communication for patients with type 2 diabetes: design of a randomised controlled trial
title_short The @RISK Study: Risk communication for patients with type 2 diabetes: design of a randomised controlled trial
title_sort @risk study: risk communication for patients with type 2 diabetes: design of a randomised controlled trial
topic Study Protocol
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2922111/
https://www.ncbi.nlm.nih.gov/pubmed/20687924
http://dx.doi.org/10.1186/1471-2458-10-457
work_keys_str_mv AT welschenlauramc theriskstudyriskcommunicationforpatientswithtype2diabetesdesignofarandomisedcontrolledtrial
AT botsandradm theriskstudyriskcommunicationforpatientswithtype2diabetesdesignofarandomisedcontrolledtrial
AT dekkerjacquelinem theriskstudyriskcommunicationforpatientswithtype2diabetesdesignofarandomisedcontrolledtrial
AT timmermansdaniellerm theriskstudyriskcommunicationforpatientswithtype2diabetesdesignofarandomisedcontrolledtrial
AT vanderweijdentrudy theriskstudyriskcommunicationforpatientswithtype2diabetesdesignofarandomisedcontrolledtrial
AT nijpelsgiel theriskstudyriskcommunicationforpatientswithtype2diabetesdesignofarandomisedcontrolledtrial
AT welschenlauramc riskstudyriskcommunicationforpatientswithtype2diabetesdesignofarandomisedcontrolledtrial
AT botsandradm riskstudyriskcommunicationforpatientswithtype2diabetesdesignofarandomisedcontrolledtrial
AT dekkerjacquelinem riskstudyriskcommunicationforpatientswithtype2diabetesdesignofarandomisedcontrolledtrial
AT timmermansdaniellerm riskstudyriskcommunicationforpatientswithtype2diabetesdesignofarandomisedcontrolledtrial
AT vanderweijdentrudy riskstudyriskcommunicationforpatientswithtype2diabetesdesignofarandomisedcontrolledtrial
AT nijpelsgiel riskstudyriskcommunicationforpatientswithtype2diabetesdesignofarandomisedcontrolledtrial